Interventional device developer Boston Scientific of Natick, MA, has released financial results for its 2005 fiscal second quarter (end-June 30).
For the period, the firm had net sales of $1.6 billion, up 11% compared with $1.5 billion reported for the second quarter of 2004. Excluding the favorable impact of $26 million in foreign currency fluctuations, net sales saw an increase of 9%, according to the company.
Reported net income for the quarter, including net special charges of $199 million, showed a downturn to $205 million, compared with reported net income of $313 million for the same period last year. The net special charges for the quarter consisted principally of purchased in-process research and development costs related to the acquisitions of TriVascular, CryoVascular Systems, and Rubicon Medical, Boston Scientific said.
By AuntMinnie.com staff writers
July 19, 2005
Related Reading
Boston Scientific nets patent legal win, July 4, 2005
Jury favors J&J over Boston Scientific on stent patent, June 22, 2005
Boston Scientific ends first enrollment phase of Liberté trial, June 21, 2005
Boston Scientific notches 400th Liberté enrollment, May 26, 2005
Boston Scientific posts strong Q1, April 20, 2005
Copyright © 2005 AuntMinnie.com
